Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint–Based Therapy in Patients With Advanced NSCLC
4/15/2021
0:00
15:06
Interview with Charu Aggarwal, MD, and Lova Sun, MD, authors of Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint Inhibitor–Based Therapy in Patients With Advanced Non–Small-Cell Lung Cancer
More episodes from "JAMA Oncology Author Interviews"
Don't miss an episode of “JAMA Oncology Author Interviews” and subscribe to it in the GetPodcast app.
